Skip to Main Content

More than two years after the Covid-19 pandemic emerged, a new scorecard finds that 19 of 26 pharmaceutical companies that marketed vaccines or therapeutics to contain the virus rank poorly when it came to complying with human rights principles.

The rankings were compiled by examining actions taken to provide access to products, including commitments and measurable targets; transparency in disclosing R&D and production costs, and profits; the extent to which international cooperation was pursued and patents were enforced; and a willingness to provide fair pricing, equitable distribution, and technology transfers, among other things.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

Create a display name to comment

This name will appear with your comment